Shots:
IMUNON has dosed the first pts with IMNN-001 in P-III (OVATION 3) trial for the treatment of women with newly diagnosed advanced ovarian cancer
Trial will evaluate IMNN-001 (100 mg/m², intraperitoneally, QW) + neoadj. & adj. CT vs CT alone in newly diagnosed stage 3C/4 ovarian cancer, incl. HRD+ pts who will receive PARP…
